Pharmaceutical Executive Europe - January 2008 - (Page 25)
Pharmaceutical Executive Europe January 2008 Pricing and Reimbursement 25 Through the Reimbursement Barriers Brian Lovatt looks at how drug companies involved in oncology can meet their pricing and reimbursement objectives as NICE-style barriers start to rise across Europe. he focus on research and development of new anti-cancer treatments is likely to produce between 50 and 55 new approved NCEs in the next five years. This is fantastic news for the sufferers of cancer, their families and friends. But the problem is, will they be approved for reimbursement? On the positive side, the cancer therapeutic area budget stood at $35 billion in 2006, double that of 2001. Should all things be equal, we can expect the market to grow 17% to 20% through to the year 2010, which will make it worth between $62 and US$70 billion.1 However, a review of the drug budgets of all world’s major countries reveals there is going to be very little additional money available to pay for all the relatively-more-expensive cancer treatments that will be approved. More money to invest in healthcare needs to be found. The number of blockbuster drugs T
http://ok.com/nxtbooks/advanstaruk/pharmexeceurope-imsoncology0907/index.php?startpage=2
Table of Contents for the Digital Edition of Pharmaceutical Executive Europe - January 2008